Nutritive potentials and utilization of garden snail (Limicolaria aurora) meat meal in the diet of Clarias gariepinus fingerlings

The possibility of using garden snail (Limicolaria aurora) meat meal as a protein source in fish feeds was tested in Clarias gariepinus fingerlings. Five isonitrogenous (43% crude protein) diets in which garden snail meat meal was used to replace fish meal at 0%, (control diet), 25, 50, 75 and 100% inclusion levels were used for the study. The fish were fed ad-libitum for 8 weeks. Garden snail meat meal used had a crude protein content of 66.76% and ash content of 4.10%, while crude protein and ash content of fishmeal used were 72.46% and 18.22% dry weight, respectively. The lipid content of garden snail meat meal and fishmeal; 7.85% and 7.97%, respectively, was not significantly different (p0.05). The mean weight gain, relative growth and specific growth rates were highest in fish fed 25% garden snail meat meal diet. The best food conversion ratio (1.21) and protein efficiency ratio (3.69) were also recorded in fish fed 25% garden snail meat meal diet. Visceral somatic indices (2.71-17.24%) increased significantly (p0.05) with increase in the garden snail meat meal inclusion in the diets

Vitamin C (ascorbic acid) requirements of Heterobranchus longifilis fingerlings

A feeding experiment was conducted to quantify the minimum dietary vitamin C requirement of Heterobranchus longifilis fingerlings. Fish were fed a basal diet with 42.5% crude protein for a conditioning period of 2 weeks. Following conditioning, fingerlings with initial mean weight, 2.3 ± 0.3 g were stocked as groups of 20 fingerlings into 30 litre tanks in a mini-flow through experimental system. Graded levels (0, 50, 100, 150, 200 and 250) mg of L-ascorbic acid kg-1 diet was included into the basal diet by replacing part of the silica component and fed to triplicate groups for 20 weeks. Fish fed the control (0 mg vitamin C kg-1) diet exhibited deficiency signs including lordosis, caudal fin deformity,skin erosion and significantly (P < 0.05) suppressed weight gain and higher condition factor. Protein efficiency ratio and specific growth rate were significantly (P < 0.05) improved with increasing levels ofvitamin C up to 200 mg kg-1 diets. Tissues (liver, kidney, gills and muscle) ascorbate concentration generally reflected dietary inclusion levels with significant (P < 0.05) lowest level occurring in thecontrol groups. The dietary requirement based on least mean squares error regression analysis of weight gain and specific growth rate data on inclusion level of vitamin C was 82.2 ± 0.2 mg vitamin C kg-1 diet which corresponds to 100 mg of vitamin C kg-1 diet

Flexible bronchoscopic management of benign tracheal stenosis: long term follow-up of 115 patients

<p>Abstract</p> <p>Background</p> <p>Management of benign tracheal stenosis (BTS) varies with the type and extent of the disease and influenced by the patient's age and general health status, hence we sought to investigate the long-term outcome of patients with BTS that underwent minimally invasive bronchoscopic treatment.</p> <p>Methods</p> <p>Patients with symptomatic BTS were treated with flexible bronchoscopy therapeutic modalities that included the following: balloon dilatation, laser photo-resection, self-expanding metal stent placement, and High-dose rate endobronchial brachytherapy used in cases of refractory stent-related granulation tissue formation.</p> <p>Results</p> <p>A total of 115 patients with BTS and various cardiac and respiratory co-morbidities with a mean age of 61 (range 40-88) were treated between January 2001 and January 2009. The underlining etiologies for BTS were post - endotracheal intubation (N = 76) post-tracheostomy (N = 30), Wegener's granulomatosis (N = 2), sarcoidosis (N = 2), amyloidosis (N = 2) and idiopathic BTS (N = 3). The modalities used were: balloon dilatation and laser treatment (N = 98). Stent was placed in 33 patients of whom 28 also underwent brachytherapy. Complications were minor and mostly included granulation tissue formation. The overall success rate was 87%. Over a median follow-up of 51 months (range 10-100 months), 30 patients (26%) died, mostly due to exacerbation of their underlying conditions.</p> <p>Conclusions</p> <p>BTS in elderly patients with co-morbidities can be safely and effectively treated by flexible bronchoscopic treatment modalities. The use of HDR brachytherapy to treat granulation tissue formation following successful airway restoration is promising.</p

Adolescent perspectives on social support received in the aftermath of sexual abuse: a qualitative study

The extent and quality of social support provided to young survivors of sexual abuse (SA) have only rarely been examined. This qualitative study aimed to investigate adolescent perspectives on social support received in the aftermath of SA. A total of 26 sexually victimized adolescents (15-18 years old) participated in a qualitative face-to-face, in-depth interview that focused on perceived social support. Qualitative content analysis was conducted as per Mayring (2008) using the qualitative data analysis program ATLAS.ti. In addition, quantitative correlational analyses were conducted to identify characteristics of SA and their associations with perceived social support. Although participants perceived parental support as the most necessary type of support, they were much more satisfied with support from peers. In particular, adolescents stated that they wished they had received more emotional support from their parents in order to better cope with the abuse. About half of participants reported having received counseling, and counseling was seen as very helpful in dealing with the consequences of SA. Only a few adolescents mentioned their school as a source of support. Intra-familial abuse, younger victim age at the time of abuse, an adult perpetrator, and severe abuse were all negatively associated with satisfaction with perceived support. Our results suggest that support for young survivors of SA needs to be improved. Prevention of SA needs particular focus on improving parental reactions to SA, facilitating access to professional support, and raising teacher awareness of the importance of their role in the provision of support for sexually victimized children

Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients

Bococizumab is a humanized monoclonal antibody that inhibits proprotein convertase subtilisin- kexin type 9 (PCSK9) and reduces levels of low-density lipoprotein (LDL) cholesterol. We sought to evaluate the efficacy of bococizumab in patients at high cardiovascular risk. METHODS In two parallel, multinational trials with different entry criteria for LDL cholesterol levels, we randomly assigned the 27,438 patients in the combined trials to receive bococizumab (at a dose of 150 mg) subcutaneously every 2 weeks or placebo. The primary end point was nonfatal myocardial infarction, nonfatal stroke, hospitalization for unstable angina requiring urgent revascularization, or cardiovascular death; 93% of the patients were receiving statin therapy at baseline. The trials were stopped early after the sponsor elected to discontinue the development of bococizumab owing in part to the development of high rates of antidrug antibodies, as seen in data from other studies in the program. The median follow-up was 10 months. RESULTS At 14 weeks, patients in the combined trials had a mean change from baseline in LDL cholesterol levels of -56.0% in the bococizumab group and +2.9% in the placebo group, for a between-group difference of -59.0 percentage points (P<0.001) and a median reduction from baseline of 64.2% (P<0.001). In the lower-risk, shorter-duration trial (in which the patients had a baseline LDL cholesterol level of ≥70 mg per deciliter [1.8 mmol per liter] and the median follow-up was 7 months), major cardiovascular events occurred in 173 patients each in the bococizumab group and the placebo group (hazard ratio, 0.99; 95% confidence interval [CI], 0.80 to 1.22; P = 0.94). In the higher-risk, longer-duration trial (in which the patients had a baseline LDL cholesterol level of ≥100 mg per deciliter [2.6 mmol per liter] and the median follow-up was 12 months), major cardiovascular events occurred in 179 and 224 patients, respectively (hazard ratio, 0.79; 95% CI, 0.65 to 0.97; P = 0.02). The hazard ratio for the primary end point in the combined trials was 0.88 (95% CI, 0.76 to 1.02; P = 0.08). Injection-site reactions were more common in the bococizumab group than in the placebo group (10.4% vs. 1.3%, P<0.001). CONCLUSIONS In two randomized trials comparing the PCSK9 inhibitor bococizumab with placebo, bococizumab had no benefit with respect to major adverse cardiovascular events in the trial involving lower-risk patients but did have a significant benefit in the trial involving higher-risk patients